- Cyclic vomiting syndrome (CVS), characterized by recurrent episodes of intense nausea and vomiting with symptom-free intervals, is gaining increased clinical recognition, prompting demand for targeted treatment and diagnostic solutions in both pediatric and adult populations across healthcare systems globally
- The rising prevalence of functional gastrointestinal disorders, growing awareness among healthcare professionals, and improvements in diagnostic capabilities are primary drivers fueling the demand for CVS-related therapeutics and supportive care options
- North America dominated the cyclic vomiting syndrome market with the largest revenue share of 42.5% in 2024, owing to higher disease awareness, advanced healthcare infrastructure, and active research into neurological and gastrointestinal overlaps contributing to CVS, especially in the U.S. where early diagnosis and access to emerging therapies are driving growth
- Asia-Pacific is expected to be the fastest growing region in the cyclic vomiting syndrome market during the forecast period due to increased healthcare access, rising awareness initiatives, and improving diagnostic rates in countries such as India and China
- The anticonvulsant drugs segment dominated the cyclic vomiting syndrome market with a market share of 39.6% in 2024, largely due to their effectiveness in reducing episode frequency and severity, especially in patients with underlying neurological conditions
